Magnesium Sulfate interactions
Full monograph for Magnesium SulfateCheck it against another medicine
Medicines
135 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amikacin | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicin | Major | Antagonism · Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or…2 documented mechanisms | 14 sources — open the full entry |
| Betamethasone + Neomycin Sulphate (Ophthalmic) | Major | Antagonism · Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or…2 documented mechanisms | 14 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Framycetin + Esculin | Major | Antagonism · Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or…2 documented mechanisms | 14 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Neomycin + Esculin | Major | Antagonism · Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or…2 documented mechanisms | 14 sources — open the full entry |
| Clobetasol Propionate + Neomycin Sulphate + Nystatin | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acid | Major | Antagonism · Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or…2 documented mechanisms | 14 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate | Major | Antagonism · Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or…2 documented mechanisms | 14 sources — open the full entry |
| Dexamethasone + Tobramycin | Major | Antagonism · Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or…2 documented mechanisms | 14 sources — open the full entry |
| Erdafitinib | Major | Others | Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be… | 1 sources — open the full entry |
| Fluocinolone Acetonide + Neomycin Sulfate | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Fluormetholone + Neomycin Sulphate | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Fluorometholone + Gentamicin | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Gentamicin + Hydrocortisone Acetate | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Gentamicin SulfateInjectionOphthalmic | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Gramacidin + Neomycin + Polymixin B | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Hydrocortisone + Neomycin Sulphate + Polymixin B | Major | Antagonism · Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or…2 documented mechanisms | 14 sources — open the full entry |
| Hydrocortisone Acetate + Neomycin Sulphate | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Kanamycin | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Loteprednol Etabonate + Tobramycin | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Metronidazole + Neomycin Sulphate + Polymyxin B + Nystatin | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Neomycin Sulfate + Bacitracin Zinc | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Neomycin Sulfate + Bacitracin Zinc + Polymyxin B Sulfate | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Neomycin Sulphate + Polymyxin B Sulphate + Pramoxine | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Prednisolone + Neomycin Sulphate + Polymixin B Sulphate | Major | Antagonism · Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or…2 documented mechanisms | 14 sources — open the full entry |
| TobramycinNebuliser SolutionOphthalmic | Major | Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or… | 7 sources — open the full entry |
| Triamcinolone + Neomycin + Nystatin + Gramicidin | Major | Antagonism · Synergy | Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of parenteral magnesium, potentially resulting in severe and/or…2 documented mechanisms | 14 sources — open the full entry |
| Acyclovir + Hydrocortisone | Moderate | Antagonism | The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy… | 7 sources — open the full entry |
| Alendronic acid | Moderate | Absorption | INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to… | 9 sources — open the full entry |
| Alendronic Acid + Vitamin D3 | Moderate | Absorption · Synergy | INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to…2 documented mechanisms | 13 sources — open the full entry |
| Algae Calcium + Vitamin D3 | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide | Moderate | Synergy | The concomitant administration of magnesium salts with other magnesium-containing preparations such as antacids or laxatives may increase the risk of magnesium… | 1 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethicone | Moderate | Synergy | The concomitant administration of magnesium salts with other magnesium-containing preparations such as antacids or laxatives may increase the risk of magnesium… | 1 sources — open the full entry |
| Aluminium Oxide + Magnesium Trisilicate | Moderate | Synergy | The concomitant administration of magnesium salts with other magnesium-containing preparations such as antacids or laxatives may increase the risk of magnesium… | 1 sources — open the full entry |
| Amlodipine Besilate | Moderate | Others | Coadministration of intravenous magnesium and nifedipine may result in hypotension and neuromuscular blockade. The mechanism is unknown. Other calcium channel… | 28 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Moderate | Others | Coadministration of intravenous magnesium and nifedipine may result in hypotension and neuromuscular blockade. The mechanism is unknown. Other calcium channel… | 28 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Others | Coadministration of intravenous magnesium and nifedipine may result in hypotension and neuromuscular blockade. The mechanism is unknown. Other calcium channel… | 28 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Others | Coadministration of intravenous magnesium and nifedipine may result in hypotension and neuromuscular blockade. The mechanism is unknown. Other calcium channel… | 28 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Moderate | Others | Coadministration of intravenous magnesium and nifedipine may result in hypotension and neuromuscular blockade. The mechanism is unknown. Other calcium channel… | 28 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Moderate | Others | Coadministration of intravenous magnesium and nifedipine may result in hypotension and neuromuscular blockade. The mechanism is unknown. Other calcium channel… | 28 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Moderate | Others | Coadministration of intravenous magnesium and nifedipine may result in hypotension and neuromuscular blockade. The mechanism is unknown. Other calcium channel… | 28 sources — open the full entry |
| Atracurium Besilate | Moderate | Synergy | Magnesium salts may enhance the effects of nondepolarizing neuromuscular blocking agents. One study showed a 25% increase in vecuronium potency after… | 2 sources — open the full entry |
| Baloxavir Marboxil | Moderate | Absorption | Coadministration with polyvalent cation-containing products may decrease the plasma concentrations and therapeutic efficacy of baloxavir. The proposed… | 3 sources — open the full entry |
| Betamethasone | Moderate | Antagonism | The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy… | 7 sources — open the full entry |
| Betamethasone + Calcipotriol | Moderate | Antagonism | The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy… | 7 sources — open the full entry |
| Betamethasone + Clotrimazole | Moderate | Antagonism | The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy… | 7 sources — open the full entry |
| Betamethasone + Phenylephrine + Lignocaine | Moderate | Antagonism | The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy… | 7 sources — open the full entry |
| Betamethasone Dipropionate | Moderate | Antagonism | The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy… | 7 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acid | Moderate | Antagonism | The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy… | 7 sources — open the full entry |
| Betamethasone Sodium Phosphate | Moderate | Antagonism | The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy… | 7 sources — open the full entry |
Conditions
Conditions in which Magnesium Sulfate needs care, as documented in this source.
Depressive Disorder
MajorAntiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication. Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior. Caregivers and family should be alert for the emergence or worsening of symptoms. Behaviors of concern should be reported immediately to the healthcare providers.
9 sources
- "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals (2002):
- "Product Information. Depakene (valproic acid)." Abbott Pharmaceutical (2001):
- "Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical (2001):
- "Product Information. Lamictal (lamotrigine)." Glaxo Wellcome (2001):
- "Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical (2001):
- "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals (2001):
- "Product Information. Vimpat (lacosamide)." UCB Pharma Inc (2008):
- "Product Information. Banzel (rufinamide)." Eisai Inc (2008):
Show all 9 sourcesShow fewer sources
- "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc (2013):
Heart Diseases
MajorThe parenteral administration of magnesium is contraindicated in patients with heart block or heart damage from myocardial infarction. These conditions may be exacerbated during magnesium infusion. High serum levels of magnesium (> 4.5 mEq/L) can cause sinus bradycardia, AV block, nodal rhythms, and bundle branch block, which can progress to asystole and cardiac arrest at magnesium levels of approximately 14 mEq/L to 15 mEq/L. If parenteral magnesium is used in patients with preexisting conduction disturbances, it should be infused at a slower rate, and cardiac function and serum magnesium level should be closely monitored. The usual precautionary measures should be observed to prevent hypermagnesemia, and IV calcium salts (e.g., calcium gluconate), pressors, cardiac pacemakers, and equipment for supportive care should be immediately available in case of acute magnesium intoxication.
3 sources
- Sherer DM, Cialone PR, Abramowicz JS, Woods JR Jr "Transient symptomatic subendocardial ischemia during intravenous magnesium sulfate tocolytic therapy." Am J Obstet Gynecol 166 (1992): 33-5
- Viskin S, Belhassen B, Laniado S "Deterioration of ventricular tachycardia to ventricular fibrillation after rapid intravenous administration of magnesium sulfate." Chest 101 (1992): 1445-7
- "Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical (2001):
Inflammatory Bowel Diseases
MajorThe use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.
6 sources
- "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc (2001):
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
- "Product Information. Neoloid (castor oil)." Paddock Laboratories Inc (2001):
- "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
- "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
Intestinal Obstruction
MajorThe use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.
8 sources
- "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc (2001):
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
- "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet (2001):
- "Product Information. Citrucel (methylcellulose)." SmithKline Beecham (2001):
- "Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc (2001):
- "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
- "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
Kidney Diseases
MajorMagnesium is eliminated by the kidney. The serum concentration of magnesium is increased in patients with renal impairment. Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time. Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication. Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function. Clinical monitoring of serum magnesium levels is recommended.
5 sources
- "Product Information. Mag-Ox 400 (magnesium oxide)." Blaine Company Inc. (2001):
- "Product Information. Uro-Mag (magnesium oxide)." Blaine Company Inc. (2001):
- "Product Information. Slow-Mag (magnesium chloride)." Searle (2001):
- "Product Information. Magonate (magnesium gluconate)." Fleming and Company (2001):
- "Product Information. Losospan (magaldrate)." Whitehall-Robbins (2001):
Myasthenia Gravis
MajorThe use of magnesium sulfate is contraindicated in patients with myasthenia gravis as it can precipitate a myasthenic crisis. Myasthenic crisis is a life-threatening condition characterized by neuromuscular respiratory failure. Symptoms of myasthenic crisis may include difficulty swallowing, ptosis, facial droop, weakness and/or difficulty breathing that may require intubation.
1 source
- "Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical (2001):
Pre-Eclampsia
MajorIntravenous magnesium should not be given to mothers with preeclampsia during the two hours preceding delivery.
1 source
- "Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical (2001):
Arrhythmias, Cardiac
ModerateThe use of osmotic laxatives preparations, containing sodium sulfate, potassium sulfate, and magnesium sulfate may cause cardiac arrhythmias. There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation. Patients with electrolyte abnormalities should have them corrected before treatment is initiated. Use caution when prescribing preparations in patients at increased risk of arrhythmias or with a history of seizures. It is recommended to conduct a pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.
1 source
- "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
Therapeutic duplication
Drug classes that overlap with Magnesium Sulfate, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
magnesium
The recommended maximum number of medicines in the 'magnesium' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'magnesium' category.
Example product in the source data (US market): Nu-mag
magnesium
The recommended maximum number of medicines in the 'magnesium' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'magnesium' category.
Example product in the source data (US market): Renacidin
magnesium
The recommended maximum number of medicines in the 'magnesium' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'magnesium' category.
Example product in the source data (US market): Prepopik
magnesium
The recommended maximum number of medicines in the 'magnesium' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'magnesium' category.
Example product in the source data (US market): Aluminum hydroxide/magnesium carbonate